Amgen tapping China promise as it builds direct presence
This article was originally published in Scrip
For Amgen, being the world's largest independent biopharmaceutical company is not enough. After having first entered China directly in 2012, setting up a local headquarters in Shanghai, the US firm has now laid out a blueprint to guide its development in this key market over the next few years.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.